Flagship Pioneering announced its newest company to emerge out of stealth mode today: Expedition Medicines. It is leveraging generative design for small molecule covalent chemistry
Co-Founder and CEO Molly Gibson explains the science behind the new company and the technology and equipment it uses for the work. Expedition has been funded with $50 million, and is also announcing a multi-target deal with Pfizer for prostate cancer.
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.